review Open AccessTop 1% cited
Biomarkers of Parkinson’s disease: Present and future
Metabolism · 2014 · Vol. 64(3) · pp. S40–S46
Diane B. Miller✉(Centers for Disease Control and Prevention)James P. O’Callaghan✉(National Institute for Occupational Safety and Health)
Health, Environment, Cognitive AgingParkinson's Disease Mechanisms and TreatmentsGenetic Neurodegenerative DiseasesNeuropathologyDiseaseSubstantia nigraMedicineParkinson's diseasePars compactaNeuroscienceContext (archaeology)BiomarkerDopaminergic
MeSH terms
Antiparkinson AgentsDopamineHumansMotor SkillsParkinson DiseasePredictive Value of TestsRisk FactorsSleep, REMSmellBiomarkersApoptosisDisease ProgressionEarly Diagnosisalpha-SynucleinNeuroimaging
Citations
399
FWCI
14.00
field-weighted impact
References
66
Percentile
99%
vs. same field & year
Citations per year
References
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Clinical Pharmacology & Therapeutics · 2001 · 6,574 citations
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Journal of Neurology · 2005 · 349 citations
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease
Movement Disorders · 2014 · 488 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.